BMEZ

BlackRock Health Sciences Trust II

Fundamental data last updated:August 16, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Financial Services

industry

Asset Management

Exchange

NYSE

County of HQ

US

Next Earnings Date

Not Scheduled

Business Summary

BlackRock Health Sciences Term Trust is a closed-end management investment company, which investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The company was founded on August 14, 2019 and is headquartered in Wilmington, DE.

 


VALUATION

P/E

2.44

Market Cap ($M USD)

$1.47B

Forward P/E

N/A

PEG

N/A

PRICE TO SALES

19.41

PRICE TO BOOK

0.91

EV / EBITDA

6.45

5-Year Average P/E

Free Cash Flow Yield

4.79%

DCF Value

$17.27

Graham Number

$76.76

Price to FCF

20.86

EV to FCF

20.90

Earnings Yield

14.84%

FCF Yield

4.79%

DIVIDEND

Yield

7.84%

Annual Payout

$3.15

Payout Ratio

52.76%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$5.96

Next Year EPS Growth Estimate

N/A

Next Year Revenue Growth Estimate

N/A

Return on Equity (ROE)

14.30%

FREE CASH FLOW

Operating Margin

305.20%

Debt-to-Equity

0.00

Piotroski F-Score

N/A

Altman Z-Score

N/A

Return on Invested Capital (ROIC)

14.30%

Current Ratio

0.00

Quick Ratio

0.00

Net Debt to EBITDA

0.01

Interest Coverage

3838.17

Gross Profit margin

89.28%

FCF PER SHARE

$1.92

REVENUE PER SHARE

$2.07

Gainseekers Quantitative Analysis

Summary

BMEZ’s valuation presents a compelling case for deep value investors. With a Price/Book ratio of 0.89, the market is undervaluing its assets, while the stock traded below its DCF Value, suggesting a potential upside. The Earnings Yield of 15.28% indicates robust profitability, yet the absence of a Forward P/E and Altman Z-score leaves some uncertainty about future growth and safety. Despite these gaps, the current metrics suggest a mispricing relative to intrinsic value, offering a potential opportunity for savvy investors.

AI Exposure / Tech Reliance

Operating within the Asset Management industry, BMEZ is well-positioned to leverage AI and tech advancements. The sector's inherent need for data analytics and automation aligns with AI trends, potentially enhancing portfolio management and client services. This adaptability could provide a competitive edge in a rapidly evolving financial landscape.

The Bull Case

For value investors, BMEZ's strengths are hard to ignore. A Return on Equity of 14.30% and an impressive Operating Margin of 305.20% highlight its capital efficiency and pricing power. The FCF Yield of 4.94% underscores its ability to generate cash, while a low Debt/Equity ratio ensures financial stability. These metrics paint a picture of a company with solid fundamentals and the capacity to deliver shareholder value.

The Bear Case

Despite its strengths, BMEZ faces structural challenges. The Price/Sales ratio of 18.86 suggests the stock is priced for perfection, potentially overvalued relative to its revenue generation. Additionally, the stock's proximity to its 52-week high could indicate technical overextension. Investors should be cautious of these valuation pressures, which might limit future appreciation.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

N/A

Average Analyst Price Target

N/A

Institutional Ownership %

1-Year Beta

0.86

Insider Buying % (6 Mo)

Distance to 52-Week High

8.67%

Distance to 52-Week Low

5.98%

EARNINGS SURPRISE %

N/A

50-DAY SMA

$14.19

200-DAY SMA

$14.68

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.